Antiviral molecules | CC50a | IC50b |
---|
|
MΦ
|
DC
|
T cells
|
MΦ*
|
DC*
|
T cells*
|
| | | |
HIV-1
Ba-L
|
HIV-1
NDK
|
HIV-1
Ba-L
|
HIV-1
NDK
|
HIV-1
Ba-L
|
HIV-1
NDK
|
C14
| >10 | >10 | >10 | 1.3 ± 01 | 0.02 ± 0.0 | 1.3 ± 0.1 | 1.8 ± 0.1 | 0.8 ± 0.0 | 0.7 ± 0.1 |
Enfuviritid (T20)
| >10 | >10 | >10 | 0.08 ± 0.1 | 8 ± 0.5 | 0.3 ± 0.0 | 0.8 ± 0.3 | 0.4 ± 0.2 | 6.7 ± 0.2 |
- *Mean ± 1 standard deviation
- aTerpenoid derivative C14 concentration (μM) that causes 50% cytotoxicity (CC50) on primary cells (MΦ, DC, T cells)
- bTerpenoid derivative C14 concentration (μM) that induces 50% infection inhibition (IC50) on primary cells (MΦ, DC, PBL)by primary X4-HIV-1NDKor R5-HIV-1Ba-L, expressed as mean ± 1 standard deviation MΦ: Macrophages; DC: Dendritic cells